Project Grant R43HL170802
Award Date
9/15/23
Completion Date
9/14/24
Dollars Obligated
$311K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $321,363 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Nucleusrx, Inc. located in Cranbury, NJ. The purpose of this 1-year project is to develop and test Nucleusrx's virtual care platform and remote intervention tool targeting post-acute care heart failure (HF) patients. The goal is to provide a safe and cost-effective discharge transition...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $400,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant will support the development of a new analytical testing device to precisely characterize lipoprotein particles in blood. Lipoproteins are key indicators of cardiovascular disease risk, as some classes contribute to the buildup of plaque in...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $265,347 Project Grant to Functional Fluidics Inc., a minority-owned, for-profit company in Detroit, Michigan. The grant funding supports the development and initial validation of a point-of-care device for assessing red blood cell sickling in sickle cell disease patients. The goal is to create a standalone, potentially CLIA-waived diagnostic system that can be...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $656,751 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Third Coast Dynamics, Inc. The grant will fund the development and validation of an AI-based platform called TCDFLOW that can provide 4D hemodynamic output directly from routine clinical anatomic images, replacing the need for the specialized 4D flow MRI technique. This will address limitations...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Arkansas. The funding supports the development of microphysiological systems to study hypoxic cardiac injury and the molecular pathways activated in oxygen gradients, with the goal of obtaining a comprehensive understanding of the cardiac response to hypoxic injury. Key research activities include using engineering and pharmacological...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $306,748 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Mechanobiologix LLC. The award, with a performance period from September 2024 to September 2025, supports the development of a stiffness-based drug discovery platform to evaluate therapeutic and preventive capabilities of anti-fibrotic drugs for Idiopathic Pulmonary Fibrosis (IPF). The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,052,276 to Lasarrus Clinic And Research Center Inc. to develop a wearable multimodal sensor system for remote monitoring of patients with chronic obstructive pulmonary disease (COPD). The project aims to enhance adherence to remote monitoring and early symptom recognition, in order to reduce COPD readmissions and healthcare costs....
This $641,544 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports the development of novel machine learning methods to address key challenges in analyzing complex biomedical data related to heart, lung, blood, and sleep (HLBS) disorders. Specifically, the project aims to: 1) propose new machine learning techniques for uncovering causal relationships between clinical...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $299,604 project grant to Case Western Reserve University. The 4-year grant, effective September 1, 2024, supports the development and validation of a novel "transfer volume regression" model to enable quantitative clinical risk predictions for major cardiovascular events, including stroke, heart attack, heart failure, and death. The project...